Replies to post #312 on Biosig Technologies Inc (BSGM)

[conix]

HIGHLIGHTS:BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.

Market Capitalization: $150 million
Current Price: $7.42 per share
YTD H-L: $9.97 - $3.50
Symbol: BSGM

*Emerging Field of Bioelectronic Medicine

*Medical Device "Pure EP" has ability to display high-fidelity cardiac recordings at previously undetectable levels; Reduces "Noise"


*Current $4.6 Billion 'EP'(Electrophysiology) market with 10% annual growth

*World-Class Management; BOD; Scientific Advisory Board

*Long Term Collaboration with the Mayo Clinic

*Aggressive M&A Activity in the sector

*FDA 510(k) clearance in 2018; Introduction to Medical Centers nationwide in '19

*First patient cases in 2019 and targeted commercial release

*NASDAQ Capital Market listed; Member of Russell 3000 Indes

*IP advisory by Sherpa Technology Group, Sterne Kessler





Website: https://www.biosig.com/

[conix]

It is extremely rare for the Mayo Clinic to invest in a medical technology. This development is extremely positive for BSGM--a due diligence plus for investors.

JMO